"mesothelioma lawyer" - Mesothelin

Mesothelin
Title: Mesothelin
Category: Medical Dictionary
Created: 11/19/2003
Last Editorial Review: 11/19/2003

Asbestos Workers Union Joins New Medical Foundation s Quest for Cure of Asbestos and Benzene-Related Cancers
The Pacific Heart, Lung and Blood Institute (”PACHLAB”) is pleased to announce the addition of Terry Lynch as a member of its Board of Directors. PACHLAB is a 501(c)(3) non-profit medical research foundation devoted to the prevention, diagnosis, and treatment of occupational diseases through independent research, collaboration, and education. Terry Lynch is Vice President at Large [...]

Study: Genetics, Not Smoking Habits, May Be Responsible For Lung Cancer Disparities Among Races
For years, scientists have argued whether genes or smoking habits are responsible for the disparities in lung cancer rates among smokers of different ethnic backgrounds. Now, a new study suggests that genetics may help explain the racial differences long seen in the disease. In a study of more than 180,000 people, one of the largest of its kind, Blacks who smoke up to a pack a day are far more likely to develop lung cancer than Whites who smoke as much. Researchers also found that Hispanic and Asian smokers were less likely than Black smokers to develop the disease, at least up to a point. The racial differences disappeared among heavy smokers, or those who puffed more than a pack and a half per day. Doctors have long known tha...

Researchers Publish New Studies And Findings In The Area Of Lung Cancer
New findings from Taiwan, the United Kingdom and Turkey describe advances in lung cancer. Study 1: Gefitinib was shown to be an effective treatment of patients with non-small cell lung cancer (NSCLC) for whom standard chemotherapy is not an option. "Gefitinib is effective in the treatment of advanced NSCLC. However, most studies have only investigated patients who have good performance status or are evaluable," scientists in Taiwan reported. "This study evaluated the efficacy of gefitinib in a consecutive series of patients with NSCLC. The treatment response of all gefitinib-treated NSCLC patients from November 2001 to September 2003 at a single medical institute was retrospectively evaluated. All patients receiving at least 1 dose...

Oxigene Commences Phase II Trial For The Treatment Of Stage IIIa/IIIb Non Small Cell Lung Cancer
Oxigene, Inc. announced that it plans to commence a phase II clinical trial in the United States for the treatment of stage IIIa/IIIb non small cell lung cancer (NSCLC). The company will evaluate its lead clinical candidate, Combretastatin A4P (CA4P), in combination with concurrent chemoradiotherapy, a widely accepted standard in the United States for the treatment of patients with all histological types of unresectable stage IIIa/IIIb NSCLC. The trial will be conducted under Oxigene's investigational new drug (IND) application on file with the U.S. Food & Drug Administration. The phase II clinical trial will commence by enrolling approximately 12 patients to assess the tolerability of the protocol and to establish the recommended dos...

Alfacell Revises Guidance on Patient Enrollment for the ONCONASE Confirmatory Phase IIIb Clinical Trial in Unresectable Malignant Mesothelioma
Bloomfield, NJ - Alfacell Corporation (Nasdaq: ACEL) today provided the following update on the Company’s international, confirmatory Phase IIIb trial evaluating ONCONASE(R) (ranpirnase), the Company’s lead investigational drug candidate, as a treatment for unresectable malignant mesothelioma (UMM): The Company expects to reach full enrollment of 316 patients for the trial ahead of the previously announced [...]